Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9653926 | 0.82 | NISCH (0.76) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL3178923 | 0.78 | NISCH (0.59) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL953493 | 0.76 | TAAR1 (1.00) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL954681 | 0.74 | TAAR1 (0.73) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL3169446 | 0.74 | HTR1D (0.61) | NISCHADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL3173211 | 0.74 | NISCH (0.63) | NISCHADRA2AADRA2BADRA2CHTR1A | |
| Hydrochloric Acid SCHEMBL9655719 | 0.72 | NISCH (0.62) | NISCHADRA2AADRA2BADRA2CHTR1A | |
| SCHEMBL546875 | 0.72 | NISCH (1.00) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL954630 | 0.72 | TAAR1 (0.68) | NISCHTAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL546268 | 0.72 | NISCH (0.78) | NISCHADRA2AADRA2BADRA2CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173720-A2 | 2-IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101687812-A | The 2-imidazolinium compounds that trace amine associated receptors (TAAR) is had good affinity | HOFFMANN LA ROCHE | 2010-03-31 | — | — | CN | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652055-B2 | 2-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018180-A1 | 2-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | US | disclosed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003868-A2 | 2 -IMIDAZOLINES HAVING A GOOD AFFINITY TO THE TRACE AMINE ASSOCIATED RECEPTORS (TAARS) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018180-A1 | 2-IMIDAZOLINES | TAAR1, TAAR5, NPY1R | NISCH 2014/4885TAAR1 1/4885ADRA2A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.